Amplimmune grants Daiichi option for autoimmune product AMP-110

Amplimmune Inc. (Rockville, Md.) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) an exclusive option to license worldwide rights to develop and commercialize Amplimmune's AMP-110. The option is exercisable through the completion of a proof-of-concept (POC) Phase II trial of the product, a fusion protein containing the extracellular domain of B7-H4 (V-set domain containing T cell activation inhibitor; VTCN1) and the Fc-portion of IgG. This half, Amplimmune and Daiichi plan to start a Phase I trial of AMP-110 for an undisclosed autoimmune indication. ...